Related Experiment Video
Updated: Jan 11, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
The Identification of Potential Treatment Targets to Reduce the Risk of Obesity-Related Complications: A Step Toward
Luca Busetto1, Volker Schnecke2, Maria Overvad2
1Department of Medicine University of Padova Padova Italy.
Aims:
Obesity-related complications (ORCs) are associated with substantial health and economic burdens. Although treatment targets are routinely used for other chronic conditions, none currently exist in obesity management. We aimed to identify an adiposity measure that indicates a reduced risk of four ORCs.
Materials And Methods:
This population-based cohort study of patients aged 18-60 years used data from the UK Clinical Practice Research Datalink Aurum. Associations between absolute 10-year ORC risk and baseline body mass index (BMI), waist-height ratio (WHtR), and changes in adiposity measures after weight loss were calculated. Absolute values and changes in adiposity measures were evaluated as a proxy for achieving an absolute 10-year ORC risk similar to that of people without obesity, and optimal cut-offs were identified based on the balance between true positive and true negative rates for achieving the treatment goal.
Results:
Absolute values of BMI and WHtR post-weight change were more strongly associated with 10-year ORC risk than relative changes; WHtR was the best proxy for a low absolute risk for type 2 diabetes, hypertension, and atherosclerotic cardiovascular disease, and BMI for hip/knee osteoarthritis. Based on the balance between true negative and true positive rates of multiple cut-offs, a BMI ≤ 27 kg/m2 and WHtR ≤ 0.53 are proposed as potential treatment targets for obesity.
Conclusions:
These findings suggest that treatment goals for obesity management may be considered on post-weight-change absolute adiposity measures, rather than relative changes. Both weight and WHtR may be considered when defining treatment targets for ORC risk reduction.
Insights
New research suggests specific body measurements after weight loss can help manage obesity-related complications. Body Mass Index (BMI) and waist-height ratio (WHtR) are proposed as key targets for reducing health risks.
Area of Science:
- Metabolic Health
- Obesity Medicine
- Cardiovascular Health
Background:
- Obesity-related complications (ORCs) pose significant health and economic challenges.
- Current obesity management lacks established treatment targets, unlike other chronic conditions.
- Identifying effective adiposity measures is crucial for risk reduction.
Purpose of the Study:
- To identify an optimal adiposity measure for reducing the risk of four major obesity-related complications.
- To evaluate absolute adiposity measures and their changes as proxies for achieving a low 10-year ORC risk.
Main Methods:
- A population-based cohort study utilizing UK Clinical Practice Research Datalink Aurum data (18-60 years).
- Analysis of associations between 10-year ORC risk and baseline/post-weight loss Body Mass Index (BMI) and waist-height ratio (WHtR).
- Identification of optimal cut-offs for BMI and WHtR based on risk reduction efficacy.
Main Results:
- Absolute post-weight change BMI and WHtR were more strongly linked to 10-year ORC risk than relative changes.
- WHtR proved the best indicator for reduced risk of type 2 diabetes, hypertension, and atherosclerotic cardiovascular disease.
- BMI was the most effective measure for hip/knee osteoarthritis risk. Proposed targets: BMI ≤ 27 kg/m² and WHtR ≤ 0.53.
Conclusions:
- Obesity treatment goals should focus on absolute adiposity measures post-weight change, not just relative reductions.
- Both BMI and WHtR are valuable metrics for setting treatment targets to mitigate ORC risk.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Atherosclerosis III: Management
Obesity
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Dosing: Obese Patients
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

